vs
Side-by-side financial comparison of Aligos Therapeutics, Inc. (ALGS) and Cardiff Oncology, Inc. (CRDF). Click either name above to swap in a different company.
Cardiff Oncology, Inc. is the larger business by last-quarter revenue ($243.0K vs $169.0K, roughly 1.4× Aligos Therapeutics, Inc.). On growth, Cardiff Oncology, Inc. posted the faster year-over-year revenue change (62.0% vs -72.1%). Over the past eight quarters, Cardiff Oncology, Inc.'s revenue compounded faster (8.9% CAGR vs -50.7%).
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for prevalent liver diseases and viral infections. Its core pipeline includes candidates for chronic hepatitis B, non-alcoholic steatohepatitis, and other liver-related disorders, advancing R&D to serve unmet global patient needs.
ALGS vs CRDF — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $169.0K | $243.0K |
| Net Profit | — | $-7.2M |
| Gross Margin | — | — |
| Operating Margin | — | -3221.0% |
| Net Margin | — | -2969.5% |
| Revenue YoY | -72.1% | 62.0% |
| Net Profit YoY | 75.8% | 38.8% |
| EPS (diluted) | — | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $169.0K | $243.0K | ||
| Q3 25 | $741.0K | $120.0K | ||
| Q2 25 | $965.0K | $121.0K | ||
| Q1 25 | $311.0K | $109.0K | ||
| Q4 24 | $606.0K | $150.0K | ||
| Q3 24 | $1.3M | $165.0K | ||
| Q2 24 | $1.1M | $163.0K | ||
| Q1 24 | $694.0K | $205.0K |
| Q4 25 | — | $-7.2M | ||
| Q3 25 | $-31.5M | $-11.3M | ||
| Q2 25 | $-15.9M | $-13.9M | ||
| Q1 25 | $43.1M | $-13.4M | ||
| Q4 24 | $-82.2M | $-11.8M | ||
| Q3 24 | $-19.3M | $-11.9M | ||
| Q2 24 | $5.1M | $-11.8M | ||
| Q1 24 | $-34.9M | $-10.0M |
| Q4 25 | — | -3221.0% | ||
| Q3 25 | -3827.4% | -9978.3% | ||
| Q2 25 | -1924.0% | -12212.4% | ||
| Q1 25 | -6187.5% | -13194.5% | ||
| Q4 24 | -3393.2% | -8381.3% | ||
| Q3 24 | -1610.5% | -7637.0% | ||
| Q2 24 | -2489.5% | -7696.3% | ||
| Q1 24 | -3176.7% | -5333.2% |
| Q4 25 | — | -2969.5% | ||
| Q3 25 | -4256.0% | -9381.7% | ||
| Q2 25 | -1643.8% | -11523.1% | ||
| Q1 25 | 13854.7% | -12324.8% | ||
| Q4 24 | -13556.1% | -7858.0% | ||
| Q3 24 | -1540.7% | -7184.8% | ||
| Q2 24 | 477.0% | -7225.8% | ||
| Q1 24 | -5023.5% | -4883.4% |
| Q4 25 | — | $-0.11 | ||
| Q3 25 | $-3.04 | $-0.17 | ||
| Q2 25 | $-1.53 | $-0.21 | ||
| Q1 25 | $-2.11 | $-0.20 | ||
| Q4 24 | $-13.10 | $-0.22 | ||
| Q3 24 | $-3.07 | $-0.25 | ||
| Q2 24 | $0.81 | $-0.26 | ||
| Q1 24 | $-5.58 | $-0.22 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $77.8M | $58.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $53.5M | $45.4M |
| Total Assets | $88.5M | $61.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $77.8M | $58.3M | ||
| Q3 25 | $99.1M | $60.6M | ||
| Q2 25 | $122.9M | $71.0M | ||
| Q1 25 | $137.9M | $79.9M | ||
| Q4 24 | $56.9M | $91.7M | ||
| Q3 24 | $74.9M | $57.7M | ||
| Q2 24 | $94.5M | $60.3M | ||
| Q1 24 | $112.7M | $67.2M |
| Q4 25 | $53.5M | $45.4M | ||
| Q3 25 | $71.8M | $48.8M | ||
| Q2 25 | $101.9M | $58.6M | ||
| Q1 25 | $116.4M | $70.9M | ||
| Q4 24 | $-29.0M | $82.9M | ||
| Q3 24 | $50.1M | $49.4M | ||
| Q2 24 | $67.2M | $52.4M | ||
| Q1 24 | $59.8M | $60.9M |
| Q4 25 | $88.5M | $61.9M | ||
| Q3 25 | $109.8M | $63.8M | ||
| Q2 25 | $134.7M | $75.7M | ||
| Q1 25 | $150.7M | $84.8M | ||
| Q4 24 | $70.1M | $97.2M | ||
| Q3 24 | $88.4M | $62.9M | ||
| Q2 24 | $108.8M | $66.1M | ||
| Q1 24 | $127.9M | $74.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-82.5M | $-6.0M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-82.5M | $-6.0M | ||
| Q3 25 | $-24.3M | $-10.8M | ||
| Q2 25 | $-15.5M | $-8.3M | ||
| Q1 25 | $-20.9M | $-12.8M | ||
| Q4 24 | $-18.4M | $-10.3M | ||
| Q3 24 | $-20.1M | $-10.5M | ||
| Q2 24 | $-19.5M | $-9.2M | ||
| Q1 24 | $-22.7M | $-7.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-10.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-7.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | -9043.3% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -3814.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | 15.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 39.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -3.85× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
